Literature DB >> 19389935

Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications.

Olga Balague1, Ana Mozos, Daniel Martinez, Luis Hernandez, Lluis Colomo, Jose Luis Mate, Julie Teruya-Feldstein, Oscar Lin, Elias Campo, Armando Lopez-Guillermo, Antonio Martinez.   

Abstract

X box-binding protein 1 (Xbp-1) is a transcription factor that is required for the terminal differentiation of B lymphocytes into plasma cells. The Xbp-1 gene is activated in response to endoplasmic reticulum stress signals, which generate a 50-kDa nuclear protein that acts as a potent transactivator and regulates the expression of genes related to the unfolded protein response. Activated Xbp-1 is essential for cell survival in plasma-cell tumors but its role in B-cell lymphomas is unknown. We analyzed the expression of activated Xbp-1 in reactive lymphoid tissues, 411 lymphomas and plasma-cell neoplasms, and 24 B-cell lines. In reactive tissues, Xbp-1 was only found in nuclear extracts. Nuclear expression of Xbp-1 was observed in occasional reactive plasma cells and in a subpopulation of Irf-4(+)/Bcl-6(-)/Pax-5(-) B cells in the light zones of reactive germinal centers, probably representing cells committed to plasma-cell differentiation. None of the low-grade lymphomas showed evidence of Xbp-1 activation; however, Xbp-1 activation was found in 28% of diffuse large B-cell lymphomas, independent of germinal or postgerminal center phenotype, as well as in 48% of plasmablastic lymphomas and 69% of plasma-cell neoplasms. Diffuse large B-cell lymphomas with nuclear Xbp-1 expression had a significantly worse response to therapy and shorter overall survival compared with negative tumors. These findings suggest that Xbp-1 activation may play a role in the pathogenesis of aggressive B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389935      PMCID: PMC2684197          DOI: 10.2353/ajpath.2009.080848

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  XBP-1 is required for biogenesis of cellular secretory machinery of exocrine glands.

Authors:  Ann-Hwee Lee; Gerald C Chu; Neal N Iwakoshi; Laurie H Glimcher
Journal:  EMBO J       Date:  2005-12-15       Impact factor: 11.598

2.  Coordination of upregulated XBP-1 and downregulated c-myc during myeloma cell differentiation induced by 2-methoxyestradiol.

Authors:  Xia Zhou; Hua Jiang; Jian Hou
Journal:  Leuk Res       Date:  2007-01-25       Impact factor: 3.156

3.  Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells.

Authors:  Alessio Delogu; Alexandra Schebesta; Qiong Sun; Katharina Aschenbrenner; Thomas Perlot; Meinrad Busslinger
Journal:  Immunity       Date:  2006-03       Impact factor: 31.745

4.  Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.

Authors:  Ulf Klein; Stefano Casola; Giorgio Cattoretti; Qiong Shen; Marie Lia; Tongwei Mo; Thomas Ludwig; Klaus Rajewsky; Riccardo Dalla-Favera
Journal:  Nat Immunol       Date:  2006-06-11       Impact factor: 25.606

5.  The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Lorinda A Soma; Fiona E Craig; Steven H Swerdlow
Journal:  Hum Pathol       Date:  2006-01-10       Impact factor: 3.466

6.  Mantle cell lymphoma with plasma cell differentiation.

Authors:  Ken H Young; Wing C Chan; Kai Fu; Javeed Iqbal; Warren G Sanger; Anne Ratashak; Timothy C Greiner; Dennis D Weisenburger
Journal:  Am J Surg Pathol       Date:  2006-08       Impact factor: 6.394

7.  Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.

Authors:  Michael P A Davies; Dong Liu Barraclough; Ceri Stewart; Kathryn A Joyce; Richard M Eccles; Roger Barraclough; Philip S Rudland; David Ross Sibson
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

8.  Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.

Authors:  Liliana Guedez; Antonio Martinez; Shumei Zhao; Angelica Vivero; Stefania Pittaluga; Maryalice Stetler-Stevenson; Mark Raffeld; William G Stetler-Stevenson
Journal:  Blood       Date:  2004-10-12       Impact factor: 22.113

9.  IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.

Authors:  Yuou Teng; Yusuke Takahashi; Makiko Yamada; Tetsuya Kurosu; Takatoshi Koyama; Osamu Miura; Tohru Miki
Journal:  Eur J Cell Biol       Date:  2007-07-24       Impact factor: 4.492

10.  The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authors:  Daniel R Carrasco; Kumar Sukhdeo; Marina Protopopova; Raktim Sinha; Miriam Enos; Daniel E Carrasco; Mei Zheng; Mala Mani; Joel Henderson; Geraldine S Pinkus; Nikhil Munshi; James Horner; Elena V Ivanova; Alexei Protopopov; Kenneth C Anderson; Giovanni Tonon; Ronald A DePinho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

View more
  11 in total

1.  Endoplasmic reticulum stress sensor IRE1α propels neutrophil hyperactivity in lupus.

Authors:  Gautam Sule; Basel H Abuaita; Paul A Steffes; Andrew T Fernandes; Shanea K Estes; Craig Dobry; Deepika Pandian; Johann E Gudjonsson; J Michelle Kahlenberg; Mary X O'Riordan; Jason S Knight
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 2.  Cellular choreography in the germinal center: new visions from in vivo imaging.

Authors:  Anja E Hauser; Steven M Kerfoot; Ann M Haberman
Journal:  Semin Immunopathol       Date:  2010-07-09       Impact factor: 9.623

3.  The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.

Authors:  Ana Mozos; Gaël Roué; Armando López-Guillermo; Pedro Jares; Elias Campo; Dolors Colomer; Antonio Martinez
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

4.  Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.

Authors:  Jennifer E Amengual; Paul Johannet; Maximilian Lombardo; Kelly Zullo; Daniela Hoehn; Govind Bhagat; Luigi Scotto; Xavier Jirau-Serrano; Dejan Radeski; Jennifer Heinen; Hongfeng Jiang; Serge Cremers; Yuan Zhang; Simon Jones; Owen A O'Connor
Journal:  Clin Cancer Res       Date:  2015-06-26       Impact factor: 12.531

5.  Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.

Authors:  Santiago Montes-Moreno; Ana-Rosa Gonzalez-Medina; Socorro-María Rodriguez-Pinilla; Lorena Maestre; Lydia Sanchez-Verde; Giovanna Roncador; Manuela Mollejo; Juan F García; Javier Menarguez; Carlos Montalbán; M Carmen Ruiz-Marcellan; Eulogio Conde; Miguel A Piris
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

Review 6.  IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies.

Authors:  Wojciech Wiese; Natalia Siwecka; Adam Wawrzynkiewicz; Wioletta Rozpędek-Kamińska; Ewa Kucharska; Ireneusz Majsterek
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

7.  Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.

Authors:  Duosha Hu; Victoria Wang; Min Yang; Shahed Abdullah; David A Davis; Thomas S Uldrick; Mark N Polizzotto; Ravindra P Veeranna; Stefania Pittaluga; Giovanna Tosato; Robert Yarchoan
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

8.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

9.  Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism.

Authors:  Tri K Nguyen; Steven Grant
Journal:  Mol Cancer Ther       Date:  2013-12-20       Impact factor: 6.261

10.  Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation.

Authors:  Ana Paula Dias Demasi; Elizabeth Ferreira Martinez; Marcelo Henrique Napimoga; Leandro Lopes Freitas; Jose Vassallo; Adriana Silva Santos Duarte; Andresa Borges Soares; Ney Soares Araujo; Vera Cavalcanti Araujo
Journal:  Virchows Arch       Date:  2013-06-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.